# Zoetis Inc. – Consensus ‘buy’ rating and 9.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/zoetis-inc.consensus-buy-rating-and-9.5-upside-potential/4121136296
- Published: 2023-12-15T13:36:18+00:00
- Author: Charlotte Edwards

**Zoetis Inc.** which can be found using ticker (ZTS) have now 11 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between $255.00 and $190.00 calculating the mean target price we
have $216.18. Now with the previous closing price of $197.41 this now indicates 
there is a potential upside of 9.5%. There is a 50 day moving average of $172.95
and the 200 day moving average is $174.77. The company has a market cap of 91.86B.
The current share price for the company is: $200.09 USD

 The potential market cap would be $100,598,672,718 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 40.83, revenue per share of $18.09
and a 13.76% return on assets.

Zoetis Inc. is an animal health company. The Company is focused on the discovery,
development, manufacture and commercialization of medicines, vaccines, diagnostic
products and services, biodevices, genetic tests and precision animal health technology.
It commercializes products across eight core species: dogs, cats and horses and 
cattle, swine, poultry, fish and sheep and within product categories, such as vaccines,
anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated
feed additives and animal health diagnostics. The Company operates through two segments:
the United States and International. Within each of these operating segments, it
offers a product portfolio for both companion animal and livestock customers. The
Company market its products in approximately 45 countries across North America, 
Europe, Africa, Asia, Australia and South America. The Company’s products are sold
in more than 100 countries.

Share on:
